NCT01868568View on ClinicalTrials.gov

Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

55

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

insulin degludec

Administered subcutaneously (s.c., under the skin).

DRUG

insulin degludec/insulin aspart 30

A single dose administered subcutaneously (s.c., under the skin).

DRUG

insulin degludec/insulin aspart 40

A single dose administered subcutaneously (s.c., under the skin).

DRUG

insulin degludec/insulin aspart 45

A single dose administered subcutaneously (s.c., under the skin).

DRUG

insulin degludec/insulin aspart 55

A single dose administered subcutaneously (s.c., under the skin).

DRUG

insulin aspart

A single dose administered subcutaneously (s.c., under the skin).

DRUG

biphasic insulin aspart 30

A single dose administered subcutaneously (s.c., under the skin).

DRUG

placebo

A single dose administered subcutaneously (s.c., under the skin).

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT01868568 - Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes | Biotech Hunter | Biotech Hunter